Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$102.2 million.

  • Karyopharm Therapeutics' Profit After Tax fell 23202.73% to -$102.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$196.0 million, marking a year-over-year decrease of 15652.17%. This contributed to the annual value of -$196.0 million for FY2025, which is 15652.17% down from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Profit After Tax is -$102.2 million, which was down 23202.73% from -$33.1 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Profit After Tax ranged from a high of $38.7 million in Q4 2021 and a low of -$102.2 million during Q4 2025
  • Over the past 5 years, Karyopharm Therapeutics' median Profit After Tax value was -$36.8 million (recorded in 2022), while the average stood at -$35.2 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first surged by 18917.34% in 2021, then tumbled by 25657.36% in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Profit After Tax stood at $38.7 million in 2021, then plummeted by 199.45% to -$38.5 million in 2022, then dropped by 8.65% to -$41.8 million in 2023, then rose by 26.43% to -$30.8 million in 2024, then crashed by 232.03% to -$102.2 million in 2025.
  • Its last three reported values are -$102.2 million in Q4 2025, -$33.1 million for Q3 2025, and -$37.3 million during Q2 2025.